<DOC>
	<DOCNO>NCT00655200</DOCNO>
	<brief_summary>This study conduct Asia . The aim observational study evaluate safety tolerability Levemir™ FlexPen™ ( Insulin Detemir ) treatment Filipino patient Type 1 Type 2 Diabetes Mellitus .</brief_summary>
	<brief_title>Observational Study Safety Tolerability Levemir™ FlexPen™ ( Insulin Detemir ) Treatment Type 1 Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Patients diagnose Type 1 Type 2 Diabetes Mellitus . Newly diagnose insulin naive patient Patients currently human insulin basal insulin Patients prescribed Levemir™ FlexPen™ ( Insulin Detemir ) therapy Usage accordance current prescribing information ( See attach prescribe information ) Previous history hypersensitivity Insulin Detemir ( Levemir™ ) excipients ( See attach prescribe information ) Contraindications warning specify current prescribing information ( See attach prescribe information ) Pregnant woman , plan become pregnant , woman breastfeed Patients already human premix premix analogue ( unless go shifted basalbolus therapy ) Children 6 year old</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>